Heart Failure

Overview of Heart Failure and Clinical Impact

• Heart failure is a complex clinical syndrome that develops in response to a myocardial insult, leaving the heart unable to pump sufficient blood to meet the metabolic and oxygen demands of tissues and organs.

• It represents a major healthcare burden and is one of the most common reasons for annual hospital admissions and readmissions, particularly among older populations.

• Patient Acuity and Placement:

  • Patients experiencing acute exacerbations typically present to the Emergency Department (ED).

  • Depending on severity, patients are admitted either to a telemetry unit for continuous cardiac monitoring or to the Intensive Care Unit (ICU).

• Systemic Consequences of Reduced Cardiac Output:

  • Decreased tissue perfusion

  • Impaired gas exchange

  • Fluid volume imbalances

  • Decreased overall functional ability

• Primary Risk Factors:

  • High blood pressure (hypertension)

  • Coronary artery disease (CAD)

  • Long-term management of hypertension and CAD to goal therapy significantly decreases the incidence of heart failure.

• Contributing Risk Factors:

  • Diabetes mellitus

  • Metabolic syndrome

  • Advanced age

  • Tobacco use

  • Vascular disease

  • Myocardial infarction (MI)

• Non-Ischemic and Secondary Etiologies:

  • Congenital cardiac anomalies (e.g., septal defects)

  • Infiltrative cardiomyopathies (e.g., sarcoidosis)

  • Infectious and inflammatory disorders (e.g., viral myocarditis)

  • Persistent cardiac dysrhythmias

  • Exposure to cardiotoxic agents (e.g., heavy alcohol consumption, illicit drug use, chemotherapy agents)

Cardiac Anatomy and Systemic Circulation Pathophysiology

• Sequential Path of Blood Flow Through the Heart:

  1. Oxygen-poor (deoxygenated) blood returns from systemic body tissues and enters the right atrium via the superior and inferior vena cava.

  2. Blood moves through the tricuspid valve into the right ventricle.

  3. Right ventricular contraction pumps blood through the pulmonic valve into the pulmonary arteries, carrying it directly to the lungs.

  4. In the pulmonary capillary beds, carbon dioxide ($CO_2$) is exchanged for oxygen ($O_2$).

  5. Oxygen-rich (oxygenated) blood returns to the heart via the pulmonary veins into the left atrium.

  6. Blood passes through the mitral (bicuspid) valve into the left ventricle.

  7. The left ventricle—the thickest and strongest chamber of the heart—pumps oxygenated blood through the aortic valve into the aorta for distribution to systemic vital organs and tissues.

• Structural Logic of Heart Failure Symptoms:

  • Clinical manifestations manifest behind the specific chamber or side of the heart that is failing.

  • Left-Sided Heart Failure Pathophysiology:

  • The left ventricle fails to pump oxygenated blood forward into systemic circulation effectively.

  • Fluid backs up into the left atrium and pulmonary veins, raising pulmonary capillary pressure and driving fluid into lung tissue (pulmonary congestion).

  • Primary clinical manifestations are respiratory in nature.

  • Memory Aid: Left = Lungs.

  • Right-Sided Heart Failure Pathophysiology:

  • The right ventricle fails to pump blood forward into the pulmonary vasculature effectively.

  • Fluid backs up into the systemic venous circulation, causing generalized venous congestion and body swelling.

  • Primary clinical manifestations are systemic.

  • Memory Aid: Right = Rest of Body.

  • Biventricular Heart Failure:

  • Progresses when failure of one side disrupts overall hemodynamics, causing dysfunction in both ventricles.

  • Manifests with combined features of pulmonary congestion and systemic venous volume overload.

Physiology of Cardiac Output and Ejection Fraction

• Cardiac Output (CO):

  • Defined as the total volume of blood pumped by the heart per minute.

  • Equation: $\text{Cardiac Output (CO)} = \text{Stroke Volume (SV)} \times \text{Heart Rate (HR)}$

  • Normal resting cardiac output is $4\text{ to }8$ $L/min$.

  • Determinants of Stroke Volume and Cardiac Output:

  • Preload: The volume of blood in the ventricles at the end of diastole (stretch).

  • Afterload: The resistance or pressure against which the ventricles must pump to eject blood.

  • Myocardial Contractility: The intrinsic force and strength of ventricular contraction.

  • Heart Rate: The frequency of cardiac contractions per minute.

  • Any interference with these four regulatory mechanisms can precipitate heart failure.

• Left Ventricular Ejection Fraction (LVEF):

  • Definition: The percentage of total blood volume present in the left ventricle at the end of diastole that is successfully pumped out into systemic circulation with the subsequent systolic contraction.

  • Normal LVEF value: $55\% \text{ to } 65\%$

• Classification of Left-Sided Failure:

  • Heart Failure with Reduced Ejection Fraction (HFrEF / Systolic Failure / "hef-ref"):

  • Pathophysiology: Represents a defect in ventricular systolic ejection and left ventricular contraction.

  • Analogous concept: A "lazy" or weak left ventricle that cannot generate sufficient pressure to eject blood forward.

  • LVEF Measurement: Characterized by an LVEF of less than $40\%$ ($< 40\%$), which may drop drastically further as disease advances.

  • Causes: Impaired contractile strength, excessive afterload, cardiomyopathies, structural mechanical defects.

  • Result: Blood backs up into the left atrium, causing fluid accumulation in pulmonary tissues and pulmonary crackles upon auscultation.

  • Heart Failure with Preserved Ejection Fraction (HFpEF / Diastolic Failure / "hef-pef"):

  • Pathophysiology: Represents a defect in ventricular diastolic relaxation and filling.

  • Analogous concept: A "stiff" or non-compliant left ventricle that cannot relax properly to fill with blood during diastole.

  • LVEF Measurement: Preserved or normal ejection fraction percentage ($\ge 50\%$ or $55\% - 65\%$).

  • Diagnostic Criteria: Presence of clinical heart failure signs and symptoms in conjunction with normal LVEF and objective evidence of diastolic dysfunction confirmed via echocardiogram or cardiac catheterization.

Endogenous Compensatory Mechanisms

• Renin-Angiotensin-Aldosterone System (RAAS):

  • Triggered by reduced renal perfusion to maintain homeostasis.

  • Promotes sodium and water retention alongside systemic vasoconstriction to elevate preload and contractility in an attempt to preserve cardiac output.

• Sympathetic Nervous System (SNS) Activation:

  • Responds to decreased cardiac output by releasing catecholamines (epinephrine and norepinephrine).

  • Catecholamines act as potent vasoconstrictors that increase heart rate and myocardial contractility.

• Ventricular Dilation:

  • An enlargement of cardiac chamber volume occurring in response to chronically elevated intra-cardiac pressures.

  • Functions initially as an adaptive mechanism to accommodate greater blood volumes, but eventually over-stretches muscle fibers and fails.

• Ventricular Hypertrophy:

  • An adaptive increase in cardiac wall thickness resulting from chronic overwork and excessive wall strain over time.

  • Initially maintains cardiac output and tissue perfusion via increased force, but long-term increases myocardial oxygen demand, degrades contractility, and elevates dysrhythmia risk.

• Ventricular Remodeling:

  • A chronic alteration in the structural geometry, shape, and cellular composition of the heart muscle.

  • Leads to increased myocardial oxygen consumption, impaired contractility, and progressive clinical deterioration.

• Limitations of Compensatory Mechanisms:

  • While adaptive short-term, these mechanisms accelerate disease progression and ultimate cardiac failure if uncorrected by medical intervention.

Major Complications of Heart Failure

• Pleural Effusion:

  • Fluid accumulation in the pleural space between the chest wall and lungs resulting from elevated vascular hydrostatic pressures.

  • Symptoms: Dyspnea, persistent cough, and chest pain.

• Cardiac Dysrhythmias and Structural Dyssynchrony:

  • Altered cardiac architecture disrupts normal electrical conduction pathways.

  • Atrial Fibrillation (A-fib) is extremely prevalent in heart failure; it impairs atrial kick, drops cardiac output, and promotes intracardiac thrombus formation and systemic emboli.

  • Patient Management: Continuous telemetry monitoring is required.

• Hepatic Congestion and Disease:

  • Venous congestion backing up into the systemic system engorges the liver, causing hepatomegaly.

  • Chronic liver congestion leads to cardiac cirrhosis, causing irreversible scar tissue formation and impaired hepatic function.

• Renal Insufficiency and Secondary Anemia:

  • Decreased cardiac output impairs renal perfusion.

  • Diagnostic Laboratory Findings: Decreased Glomerular Filtration Rate (GFR), elevated Blood Urea Nitrogen (BUN), elevated serum creatinine, decreased urine output, increased renal sodium and water retention.

  • Renal Hypoxia and Anemia: Reduced oxygen delivery to the kidneys disrupts erythropoietin synthesis (erythropoiesis), making chronic renal insufficiency the primary cause of anemia in heart failure patients.

Diagnostic Evaluations for Heart Failure

• History and Physical Examination:

  • Comprehensive assessment focusing on clinical signs, symptoms, airway, breathing, and circulation (ABCs).

• Echocardiogram (Echo):

  • A non-invasive cardiac ultrasound that visualizes internal heart structures.

  • Evaluates chamber sizes, wall motion/thickness, overall ventricular function, LVEF, valvular structure/function, presence of effusions or intra-cardiac thrombi, and differentiates HFrEF from HFpEF.

• Electrocardiogram (EKG) and Holter Monitoring:

  • Assesses electrical conduction and cardiac rhythms.

  • Standard EKG provides a $6\text{-second}$ diagnostic strip snapshot.

  • Holter monitors provide continuous ambulatory monitoring over $24\text{ hours}$, $48\text{ hours}$, $1\text{ week}$, or up to $1\text{ month}$.

• Chest X-Ray:

  • Visualizes anatomical cardiac outline, structural cardiomegaly, and pulmonary vascular congestion or pleural effusions.

• Six-Minute Walk Test:

  • Assesses functional endurance, exercise tolerance, and oxygen saturation during active exertion.

• Cardiac Stress Testing:

  • Evaluates continuous telemetry and cardiac response during physical treadmill exercise to detect exercise-induced ischemia or dysrhythmias.

• Cardiac Magnetic Resonance Imaging (MRI):

  • Provides high-resolution imaging to evaluate myocardial tissue characteristics and structural alterations.

• Cardiac Catheterization:

  • Invasive diagnostic procedure inserting catheters into coronary vessels to directly evaluate vessel patency, measure intra-cardiac pressures, identify structural malformations, and perform interventional stent placement when blockages are present.

• Serum B-Type Natriuretic Peptide (BNP / Pro-BNP):

  • A peptide neurohormone produced and released primarily by the left ventricle in response to increased cardiac wall stretch, strain, and volume overload.

  • Diagnostic Values:

  • Normal level: Less than $100\,pg/mL$ ($< 100\,pg/mL$).

  • Markedly elevated (frequently reaching several thousand) during acute heart failure exacerbations.

Acute Decompensated Heart Failure (ADHF) and Pulmonary Edema

• Clinical Definition of ADHF:

  • A sudden escalation in heart failure signs and symptoms coupled with a decline in functional status, requiring urgent escalation of medical therapy and hospital admission.

  • Serves as the primary cause of hospitalizations among older adults in the United States.

• Progression of Pulmonary Congestion:

  1. Elevated pulmonary venous pressure forces fluid across pulmonary capillary membranes into the interstitial space faster than the lymphatic system can drain it, producing interstitial edema.

  2. The patient develops tachypnea and increasing respiratory distress.

  3. Rising pulmonary venous pressure disrupts the alveolar membrane barrier, driving fluid directly into the alveoli to cause alveolar edema.

  4. Arterial Blood Gas (ABG) Deterioration: Manifests with reduced arterial oxygen tension ($PaO_2$), elevated carbon dioxide ($CO_2$), and progressive respiratory acidosis.

• Pulmonary Edema and Flash Pulmonary Edema:

  • An acute, life-threatening medical emergency where alveoli become filled with serosanguinous fluid. Flash pulmonary edema occurs extremely rapidly.

  • Manifestations of Pulmonary Edema:

  • Severe respiratory distress: Dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND), and jugular venous distension (JVD).

  • Early Clinical Clue: Persistent coughing in chronic heart failure patients.

  • Patient Appearance: Severe anxiety, pallor, cold extremities, ashy or cyanotic skin, and cutaneous mottling secondary to intense peripheral vasoconstriction.

  • Respiratory Rate: Often exceeds $30\,breaths/min$ ($> 30\,breaths/min$) with prominent use of accessory respiratory muscles.

  • Pathognomonic Expectoration: Pink, frothy sputum is a classic sign of severe pulmonary edema.

  • Auscultation Findings: Diffuse crackles and wheezes throughout all lung fields.

  • Cardiac Parameters: Marked tachycardia, presence of abnormal $S_3$ or $S_4$ heart sounds, and potential hypotension (indicating severe ventricular failure and impending cardiogenic shock).

Clinical Interventions and Nursing Care in ADHF

• Continuous Monitoring Requirements:

  • Vital signs, oxygen saturation ($SpO_2$), cardiac rhythm (EKG/telemetry), strict Intake and Output (I&O), daily weight measurements, and frequent assessment of neurological mentation (to gauge cerebral perfusion).

  • Indicators of Fluid Volume Overload: Peripheral edema, ascites, JVD, $S_3$ heart sound, lung crackles, hypoxia, and deteriorating renal laboratory markers.

  • Indicators of Hypoperfusion: Hypotension, oliguria/decreased urine output, cool extremities, altered mental status, heart murmurs, dysrhythmias, and worsening liver and renal function tests.

• Non-Pharmacological Positioning:

  • Place dyspneic patients in High Fowler's position with feet horizontal in bed or dangling over the bedside.

  • Rationale: Pools blood in lower extremities to decrease venous return (preload) while expanding thoracic volume for improved pulmonary ventilation.

• Dietary Restraints:

  • Strict dietary sodium restrictions and fluid intake limitations.

• Pharmacological Management of ADHF:

  • Diuretics:

  • First-line medical therapy for volume overload.

  • Mechanism: Inhibits sodium reabsorption at renal tubular sites, enhancing renal sodium and water excretion.

  • Indicators of Therapeutic Efficacy: Increased urine output, symptom reduction, and rapid weight loss.

  • Key Safety Monitoring: Watch closely for hypokalemia and hypomagnesemia; administer electrolyte replacements as needed.

  • Intravenous Vasodilators (e.g., IV Nitroglycerin):

  • Indicated for ADHF patients who are not hypotensive.

  • Mechanism: Venodilator that reduces right heart preload, slightly reduces afterload, and dilates coronary arteries to enhance myocardial perfusion.

  • Administration Rules: Administered exclusively as a continuous IV infusion in an ICU setting with continuous blood pressure monitoring.

  • Morphine Sulfate:

  • Mechanism: Dilates pulmonary and systemic vascular beds to reduce both preload and afterload.

  • Benefits: Relieves respiratory distress, dyspnea, and associated anxiety via small IV boluses.

  • Key Safety Monitoring: Monitor closely for respiratory depression, which may necessitate mechanical ventilation.

  • Inotropic Agents (e.g., Dobutamine, Dopamine, Milrinone):

  • Mechanism: Increases myocardial contractility to enhance cardiac output.

  • Indication: Reserved for patients with low cardiac output and impaired perfusion who have not responded to diuretics, vasodilators, and morphine.

  • Therapeutic Evaluation: Improved cardiac output, elevated blood pressure, increased urine output, and decreased cardiac filling pressures.

  • Usage Warning: Recommended only for short-term management. Requires continuous cardiac telemetry monitoring due to the high risk of precipitating life-threatening dysrhythmias.

Clinical Manifestations of Chronic Heart Failure

• Overview:

  • Chronic heart failure represents a slower, less hyperacute manifestation of the same underlying pathophysiological mechanisms seen in ADHF. Refer to textbook Table 38.5 for specific diagnostic comparisons between right-sided and left-sided heart failure.

• Systemic Manifestations:

  • Fatigue:

  • Caused by decreased cardiac output, impaired peripheral tissue perfusion, and secondary anemia.

  • Dyspnea:

  • The most common clinical manifestation of chronic heart failure. Caused by elevated pulmonary vascular pressure secondary to interstitial and alveolar edema.

  • Initially occurs during mild physical exertion but progresses to dyspnea at rest as failure advances.

  • Orthopnea:

  • Dyspnea occurring when assuming a recumbent (flat) position due to fluid redistribution from the lower extremities into pulmonary circulation.

  • Relieved by sitting upright.

  • Nursing Assessment: Inquire about the number of pillows used at night or if the patient sleeps upright in a recliner.

  • Paroxysmal Nocturnal Dyspnea (PND):

  • Episodic, sudden respiratory distress that awakens the patient from sleep in a state of panic.

  • Pathophysiology: Reabsorption of fluid from dependent tissues into pulmonary circulation while supine, leading to alveolar flooding.

  • Patients awaken feeling suffocated with an urgent drive to sit or stand upright.

  • Cough:

  • Chronic, non-productive cough that worsens when supine, driven by pulmonary vascular congestion.

  • Tachycardia:

  • An early compensatory mechanism driven by SNS activation to offset low stroke volume. Chronic, persistent tachycardia increases myocardial oxygen demand and worsens cardiac degradation.

  • Palpitations:

  • Sensations of rapid, fluttering, or "skipping" heartbeats secondary to cardiac dysrhythmias, most commonly Atrial Fibrillation.

  • Edema:

  • Occurs in dependent body regions (legs, sacrum, scrotum if bedbound), abdominal cavity (ascites), liver, and lungs.

  • Depressing edematous tissue leaves a transient indentation termed pitting edema.

  • Long-standing chronic edema can produce cutaneous hyperpigmentation characterized by a brownish discoloration.

  • Skin and Perfusion Alterations:

  • Low cardiac output and peripheral vasoconstriction cause cool extremities and mottling (a patchy blue or gray skin discoloration).

  • Neurological Manifestations:

  • Cerebral hypoperfusion and hypoxia produce dizziness, lightheadedness, near-syncope, syncope, confusion, forgetfulness, impaired concentration, and restlessness.

  • Requires screening for confounding conditions such as cerebrovascular accident (CVA), transient ischemic attack (TIA), depression, or anxiety.

  • Gastrointestinal & Sleep Alterations:

  • Nocturia disrupts sleep due to fluid reabsorption and enhanced renal perfusion when supine at night.

  • Snoring and daytime drowsiness indicate obstructive sleep apnea, a frequent co-morbidity.

  • Abdominal fullness from ascites and hepatomegaly causes severe nausea and anorexia.

  • Chest Pain (Angina):

  • Results from reduced myocardial perfusion paired with underlying CAD, or from direct myocardial wall stretching caused by volume overload.

Pharmacotherapy and Management of Chronic Heart Failure

• General Management Strategies:

  • Frequent vital sign assessments, supplemental oxygen as required, continuous telemetry monitoring, daily morning weight tracking, strict intake and output (I&O) recording, sodium and fluid dietary restrictions, and enrollment in outpatient cardiac rehabilitation programs upon discharge.

• Angiotensin-Converting Enzyme (ACE) Inhibitors:

  • First-line pharmacological agents for chronic heart failure.

  • Mechanism: Inhibits systemic vasoconstriction and aldosterone release, reducing afterload and systemic vascular resistance (SVR) while suppressing progressive ventricular hypertrophy and remodeling.

  • Adverse Effects: Symptomatic hypotension, persistent dry cough, hyperkalemia, renal insufficiency, and angioedema (a life-threatening allergic reaction involving rapid swelling of the face, lips, tongue, and respiratory airways).

  • Nursing Monitoring: Monitor serum potassium, BUN, and serum creatinine levels.

• Angiotensin Receptor Blockers (ARBs):

  • Indicated for patients unable to tolerate ACE inhibitors (e.g., due to intractable cough or history of angioedema).

  • Mechanism: Blocks Angiotensin II receptors to promote systemic vasodilation and afterload reduction.

  • Nursing Monitoring: Same monitoring requirements as ACE inhibitors (hyperkalemia and renal labs).

• Diuretics and Aldosterone Antagonists:

  • Function: Relieves fluid volume overload, peripheral edema, and elevated pulmonary venous pressures in both HFrEF and HFpEF.

  • Loop and Thiazide Diuretic Adverse Effects: Hypokalemia, ototoxicity (hearing impairment), and allergic sensitivity in patients with sulfa-type drug allergies.

  • Spironolactone (Aldactone):

  • A potassium-sparing aldosterone antagonist diuretic.

  • Clinical Role: Serves as a safer diuretic alternative for patients prone to hypokalemia, as it promotes sodium excretion while retaining serum potassium.

• Beta-Blockers:

  • Mechanism: Directly blocks the harmful, chronic effects of SNS activation (such as persistent tachycardia) on the failing myocardium and improves overall LVEF over time.

  • Dosing Principle: Titrated progressively up to the highest tolerated dose.

  • Usage Caution: Because beta-blockers exert negative inotropic effects (reducing contractility), extreme caution must be exercised when administering to patients in active fluid volume overload.

  • Adverse Effects: Initial exacerbation of heart failure symptoms, hypotension, fatigue, and severe bradycardia.

• Digitalis Glycosides (Digoxin):

  • Clinical Status: Prescribed less frequently today due to modern pharmacological options, but maintained in patients stabilized on long-term therapy or those remaining symptomatic despite optimal management.

  • Mechanism: Enhances contractility and decreases heart failure hospitalizations and clinical symptoms.

  • Digitalis Toxicity: Requires strict monitoring for clinical signs of toxicity, notably visual disturbances such as yellow-green halos around light sources.

Advanced Heart Failure, Technology, and End-of-Life Care

• Health Promotion and Primary Prevention:

  • Aggressively manage modifiable risk factors: achieve optimal blood pressure control, manage diabetes, promote weight loss, enforce low-sodium dietary modifications, encourage exercise, and mandate tobacco cessation.

  • Administration of routine recommended vaccinations to prevent respiratory infections that trigger acute exacerbations.

  • Surgical Interventions: Valvular repair or replacement for contributing valve dysfunction; coronary revascularization (e.g., CABG or percutaneous intervention) for underlying CAD; anti-dysrhythmic medications or cardiac pacing therapy for conduction defects.

• Disease Prognosis:

  • The estimated $5\text{-year}$ survival rate for heart failure is worse than most forms of clinical cancer.

  • Frequent emergency room visits and recurrent hospital readmissions for ADHF indicate end-stage clinical progression.

• Therapeutic Options for End-Stage Heart Failure:

  1. Continuous outpatient chronic inotropic infusions.

  2. Mechanical Circulatory Support (MCS) devices.

  3. Palliative care and hospice care (with optional deactivation of internal cardiac devices).

  4. Heart transplantation.

• Left Ventricular Assist Devices (LVAD):

  • A prominent mechanical circulatory support device designed to assist or replace the pumping function of the failing left ventricle.

  • Clinical Use: Utilized as a "bridge to transplantation" while patients await a donor heart, or as lifetime destination therapy for non-transplant candidates.

  • Equipment and Safety Profile: Components include an internal pump connected to external battery packs and control units worn outside the body.

  • Critical Nursing Safety Warning: External power cables and system drivelines must never be severed or disconnected, as continuous power is mandatory to sustain life.

  • Mortality Reduction: Initiating MCS before the onset of profound right ventricular failure and secondary multi-organ system failure significantly decreases mortality and improves quality of life.

• End-of-Life and Palliative Management:

  • Advance Directives: Formalizing patient directives regarding resuscitation and advanced life support.

  • Implantable Cardioverter-Defibrillator (ICD) Management: Discussions regarding turning off the shock features of an ICD to prevent painful, inappropriate countershocks during end-stage terminal dying processes.

  • Transition to palliative care and hospice to maximize comfort and support patient and family goals as the disease progresses.